NCT02122380View on ClinicalTrials.gov

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 1, 2019

Study Completion Date

August 1, 2019

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Sitagliptin

Sitagliptin 100 mg by mouth daily for 30 Days

DRUG

Placebo

1 placebo pill by mouth per day for 30 days

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University

OTHER

NCT02122380 - The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome | Biotech Hunter | Biotech Hunter